Low-Density Lipoprotein Cholesterol Target Attainment in Patients Surviving an Acute Coronary Syndrome in Thailand: Results From the Dyslipidaemia International Study (DYSIS) II.

BACKGROUND: Patients suffering an acute coronary syndrome (ACS) are at increased risk for future cardiovascular events. Effective management of hyperlipidaemia in such patients is essential. We aimed to document the use of lipid-lowering therapy (LLT) and low-density lipoprotein cholesterol (LDL-C) target achievement in patients hospitalised with an ACS in Thailand. METHODS: The Dyslipidemia International Study (DYSIS) II was a multinational, observational study that enrolled patients over 18 years of age who were hospitalised with an ACS in 2013-2014 and survived until discharge. Patients were analysed according to whether or not they were treated with LLT prior to hospital admission. A lipid profile was carried forward from blood taken within the first 24 hours after admission, and attainment of the LDL-C target of <70 mg/dL (1.8 mmol/L) for very high-risk subjects was reported. Details of LLTs were collected. Lipid levels, LLT use and cardiovascular events since discharge were collected at a follow-up interview 4 months later. RESULTS: A total of 320 ACS patients were enrolled from seven sites across Thailand, 188 (58.8%) of whom were being treated with LLT prior to the acute event. The mean LDL-C levels of the LLT and no LLT patients were 106.2 ± 39.4 mg/dL (2.75 ± 1.02 mmol/L) and 139.8 ± 46.6 mg/dL (3.62 ± 1.21), respectively, with 15.4% and 4.5% having an LDL-C level below 70 mg/dL (1.8 mmol/L). Lipid-lowering therapy consisted mainly of statins, with an atorvastatin-equivalent daily dosage of 17 ± 13 mg/day. At the 4-month follow-up, LDL-C target attainment remained low at 26.7% for the initial LLT group and 24.1% for the no LLT group. Although most patients were being treated with LLT at this point, the dosage was still low (28 ± 16 mg/day) and there was little use of combination therapy. CONCLUSION: In this cohort of Thai ACS patients, LDL-C levels were highly elevated, placing them at extreme risk of recurrent adverse cardiovascular events. Lipid-lowering therapy was widely used after the ACS; however, treatment was rarely optimised. Huge improvements are required in the management of hyperlipidaemia in Thailand.

Determining the Site of Accessory Pathways in Orthodromic Reciprocating Tachycardia by Using the Response to Right Ventricular Pacing.

BACKGROUND: Postpacing interval (PPI) after right ventricular (RV) pacing entrainment minus tachycardia cycle length (TCL) with a correction for atrioventricular (AV) node delay (corrected PPI-TCL) was useful to differentiate atrioventricular node reentrant tachycardia (AVNRT) from orthodromic reciprocating tachycardia (ORT). However, the value of corrected PPI-TCL in determining the site of the accessory pathway (AP) in ORT has not been investigated. The purpose of this study was to assess whether the corrected PPI-TCL is useful in differentiating ORT using a left-sided AP from a right-sided AP. METHODS: We studied 52 patients with ORT using a left-sided AP and 13 patients with a right-sided AP. The PPI was measured upon cessation of the RV pacing at a cycle length 10-40 ms shorter than the TCL. The corrected PPI-TCL was calculated from the subtraction of the increment in AV nodal conduction time of the first PPI from the PPI-TCL. RESULTS: The mean corrected PPI-TCL was 83 ± 20 ms in patients with ORT using a left-sided AP and 27 ± 19 ms in patients with a right-sided AP (P ≤ 0.001). All patients with ORT using a left-sided AP except three patients with left septal AP and none of the patients with ORT using a right-sided AP had a corrected PPI-TCL > 55 ms. CONCLUSIONS: The corrected PPI-TCL after the RV pacing entrainment is useful to guide differentiating ORT using a left-sided AP from a right-sided AP.

Prospective randomized study to assess the efficacy of site and rate of atrial pacing on long-term progression of atrial fibrillation in sick sinus syndrome: Septal Pacing for Atrial Fibrillation Suppression Evaluation (SAFE) Study.

BACKGROUND: Atrial-based pacing is associated with lower risk of atrial fibrillation (AF) in sick sinus syndrome compared with ventricular pacing; nevertheless, the impact of site and rate of atrial pacing on progression of AF remains unclear. We evaluated whether long-term atrial pacing at the right atrial (RA) appendage versus the low RA septum with (ON) or without (OFF) a continuous atrial overdrive pacing algorithm can prevent the development of persistent AF. METHODS AND RESULTS: We randomized 385 patients with paroxysmal AF and sick sinus syndrome in whom a pacemaker was indicated to pacing at RA appendage ON (n=98), RA appendage OFF (n=99), RA septum ON (n=92), or RA septum OFF (n=96). The primary outcome was the occurrence of persistent AF (AF documented at least 7 days apart or need for cardioversion). Demographic data were homogeneous across both pacing site (RA appendage/RA septum) and atrial overdrive pacing (ON/OFF). After a mean follow-up of 3.1 years, persistent AF occurred in 99 patients (25.8%; annual rate of persistent AF, 8.3%). Alternative site pacing at the RA septum versus conventional RA appendage (hazard ratio=1.18; 95% confidence interval, 0.79-1.75; P=0.65) or continuous atrial overdrive pacing ON versus OFF (hazard ratio=1.17; 95% confidence interval, 0.79-1.74; P=0.69) did not prevent the development of persistent AF. CONCLUSIONS: In patients with paroxysmal AF and sick sinus syndrome requiring pacemaker implantation, an alternative atrial pacing site at the RA septum or continuous atrial overdrive pacing did not prevent the development of persistent AF. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. UNIQUE IDENTIFIER: NCT00419640.

Recent onset atrial fibrillation: baseline data from Thai subset of RECORD AF study.

BACKGROUND: The RECORD AF study is the first worldwide, prospective, observational 1-year longitudinal survey of real-life management of patients with recently diagnosed atrial fibrillation (AF). The authors present here the baseline data of Thai subset of the study. MATERIAL AND METHOD: The study enrolled consecutive patients of age > or = 18 years, presenting with and treated for AF (< or = 1 year from diagnosis), visiting office- or hospital-based cardiologists. The main primary objectives were to assess therapeutic success and clinical outcomes in rhythm- and rate-control strategies. RESULTS: Of 209 patients recruited between July and December 2007, 200 were eligible for evaluation (mean age: 62.8 years, SD 12.4; 51% males). Hypertension (49%) and dyslipidemia (36%) were the most common underlying cardiovascular diseases (CVDs). Thirty-six point nine percent of patients were at high risk of stroke (CHADS, score > or = 2). In the previous year 93 (52%) patients were diagnosed with paroxysmal AF and 86 (48%) patients with persistent AF. Rate-control was the main treatment strategy used in 151 (75.50%) of the patients, and was more frequently used in persistent AF (94.20%) than paroxysmal AF (61.3%). The most frequent medication used for rhythm-control strategy was amiodarone (83.7%) and, for rate-control strategy, it was beta-blockers (57%). For antithrombotic medication, antiplatelet agents were used in 92 (46%) patients and oral anticoagulation in 86 (43%) patients. CONCLUSION: For Thai patients with AF, hypertension and dyslipidemia were the most common underlying CVDs, and rate control was the preferred treatment strategy. The prospective 1-year data will provide insights on current AF treatment strategies.

The relationship between plasma NT-proBNP level and pacing mode in the patient with implanted permanent pacemaker.

BACKGROUND AND OBJECTIVE: Plasma BNP is current one of the prognostic markers for cardiovascular disease including congestive heart failure. The objective of the present study was to evaluate the level of plasma NT-proBNP in patients who have had permanent pacemaker implantation. MATERIAL AND METHOD: The clinical characteristics and the plasma NT-proBNP level were recorded and obtained from 284 patients with implanted permanent pacemaker followed-up at the Pacemaker Clinic, Siriraj Hospital. The factors associated with abnormal NT-proBNP level were analyzed. RESULTS: Among 284 patients who participated in the present study, 140 patients had NT-proBNP in normal range (level of < 300 pg/ml). 68 patients had NT-proBNP level between 300 to 900 pg/m/ and 76 patients had NT-proBNP level > 900 pg/ml. There were significant correlations between log NT-proBNP with patient's age, left ventricular ejection fraction and serum creatinine level with age and serum creatinine showing positive correlation and left ventricular ejection fraction having a negative correlation. From multiple regression analysis, three factors were associated with high NT-proBNP level: older age, serum creatinine level and ventricular based pacing. The patients with ventricular based pacing mode had higher NT-proBNP level than patients with atrial based pacing mode even after being adjusted for age and serum creatinine adjusted CONCLUSION: In the patient with permanent pacemaker three factors are associated with high NT-proBNP level. These are older age, serum creatinine level, and ventricular based pacemaker.

Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease.

BACKGROUND: The most common apolipoprotein E (apoE) gene polymorphism has been found to influence plasma lipid concentration and its correlation with coronary artery disease (CAD) has been extensively investigated in the last decade. It is, however, unclear whether apoE gene polymorphism is also associated with increased risk of type 2 diabetes mellitus (T2DM). The knowledge of this study may provide the primary prevention for T2DM and CAD development before its initiation and progression. Therefore, this study was carried out to determine the association between apoE gene polymorphism and T2DM with and without CAD and its role in lipid metabolism. METHODS: The case-control study was carried out on a total of 451 samples including 149 normal control subjects, 155 subjects with T2DM, and 147 subjects with T2DM complicated with CAD. The apoE gene polymorphism was tested by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Univariable and multivariable logistic regression analyses were used to identify the possible risks of T2DM and CAD. RESULTS: A significantly increased frequency of E3/E4 genotype was observed only in T2DM with CAD group (p = 0.0004), whereas the ε4 allele was significantly higher in both T2DM (p = 0.047) and T2DM with CAD (p = 0.009) as compared with controls. E3/E4 genotype was also the independent risk in developing CAD after adjusting with established risk factors with adjusted odds ratio (OR) 2.52 (95%CI 1.28-4.97, p = 0.008). The independent predictor of individuals carrying ε4 allele still remained significantly associated with both CAD (adjusted OR 2.32, 95%CI 1.17-4.61, p = 0.016) and T2DM (adjusted OR 2.04, 95%CI 1.07-3.86, p = 0.029). After simultaneously examining the joint association of E3/E4 genotype combined with either obesity or smoking the risk increased to approximately 5-fold in T2DM (adjusted OR 4.93, 95%CI 1.74-13.98, p = 0.003) and 10-fold in CAD (adjusted OR 10.48, 95%CI 3.56-30.79, p < 0.0001). The association between apoE genotypes on plasma lipid levels was compared between E3/E3 as a reference and E4-bearing genotypes. E4-bearing genotypes showed lower HDL-C and higher VLDL-C and TG, whereas other values of plasma lipid concentrations showed no significant difference. CONCLUSIONS: These results indicate that ε4 allele has influence on lipid profiles and is associated with the development of both T2DM with and without CAD, and furthermore, it increased the risk among the subjects with obesity and/or smoking, the conditions associated with high oxidative stress.

2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary.

The consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for cardiologists, neurologists, geriatricians, and general practitioners in the Asia-Pacific region. In these years, many important new data regarding stroke prevention in AF were reported. The practice guidelines subcommittee members comprehensively reviewed updated information on stroke prevention in AF, and summarized them in this 2021 focused update of the 2017 consensus guidelines of the APHRS on stroke prevention in AF. We highlighted and focused on several issues, including the importance of the AF Better Care pathway, the advantages of non-vitamin K antagonist oral anticoagulants (NOACs) for Asians, the considerations of use of NOACs for Asian AF patients with single one stroke risk factor beyond gender, the role of lifestyle factors on stroke risk, the use of oral anticoagulants during the "coronavirus disease 2019" pandemic, etc. We fully realize that there are gaps, unaddressed questions, and many areas of uncertainty and debate in the current knowledge of AF, and the physician's decision remains the most important factor in the management of AF.

2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation.

The consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for cardiologists, neurologists, geriatricians, and general practitioners in Asia-Pacific region. In these years, many important new data regarding stroke prevention in AF were reported. The Practice Guidelines subcommittee members comprehensively reviewed updated information on stroke prevention in AF, and summarized them in this 2021 focused update of the 2017 consensus guidelines of the APHRS on stroke prevention in AF. We highlighted and focused on several issues, including the importance of AF Better Care (ABC) pathway, the advantages of non-vitamin K antagonist oral anticoagulants (NOACs) for Asians, the considerations of use of NOACs for Asian patients with AF with single 1 stroke risk factor beyond gender, the role of lifestyle factors on stroke risk, the use of oral anticoagulants during the "coronavirus disease 2019" (COVID-19) pandemic, etc. We fully realize that there are gaps, unaddressed questions, and many areas of uncertainty and debate in the current knowledge of AF, and the physician's decision remains the most important factor in the management of AF.

Multiparameter diagnostic sensor measurements during clinically stable periods and worsening heart failure in ambulatory patients.

AIMS: This study aims to characterize the range of implantable device-based sensor values including heart sounds, markers of ventilation, thoracic impedance, activity, and heart rate for patients with heart failure (HF) when patients were deemed to be in clinically stable periods against the time course of acute decompensation and recovery from HF events. METHODS AND RESULTS: The MultiSENSE trial followed 900 patients implanted with a COGNIS CRT-D for up to 1 year. Chronic, ambulatory diagnostic sensor data were collected and evaluated during clinically stable periods (CSP: unchanged NYHA classification, no adverse events, and weight change ≤2.27 kg), and in the timeframe leading up to and following HF events (HF admissions or unscheduled visits with intravenous HF treatment). Physiologic sensor data from 1667 CSPs occurring in 676 patients were compared with those data leading up to and following 192 HF events in 106 patients. Overall, the mean age was 66.6 years, and the population were predominantly male (73%). Patients were primarily in NYHA II (67%), with a mean LVEF of 29.6% and median NT-proBNP of 754.5 pg/mL. Sensor values during CSP were poorer in patients who had HF events during the study period than those without HF events, including first heart sound (S1: 2.18 ± 0.84 mG vs. 2.62 ± 0.95 mG, P = 0.002), third heart sound (S3: 1.13 ± 0.36 mG vs. 0.91 ± 0.30 mG, P < 0.001), thoracic impedance (45.66 ± 8.78 Ohm vs. 50.33 ± 8.43 Ohm, P < 0.001), respiratory rate (19.09 ± 3.10 br/min vs. 17.66 ± 2.39 br/min, P = 0.002), night time heart rate (73.39 ± 8.36 b.p.m. vs. 69.56 ± 8.09 b.p.m., P = 0.001), patient activity (1.69 ± 1.84 h vs. 2.56 ± 2.20 h, P = 0.006), and HeartLogic index (11.07 ± 12.14 vs. 5.31 ± 5.13, P = 0.001). Sensor parameters measured worsening status leading up to HF events with recovery of values following treatment. CONCLUSIONS: Device-based physiologic sensors not only revealed progressive worsening leading up to HF events but also differentiated patients at increased risk of HF events when presumed to be clinically stable.

Paraoxonase 1 polymorphisms as the risk factor of coronary heart disease in a Thai population.

OBJECTIVE: Two common polymorphisms of the paraoxonase (PON1) gene, L55M and Q192R, were proven to mitigate atherosclerosis pathogenesis by protecting lipoproteins against peroxidation. This study was to evaluate the associations between both PON1 gene polymorphisms in Thai hyperlipidaemia with and without coronary heart disease (CHD). METHODS: Both PON1 genotypes were determined using PCR-RFLP in 103 healthy control subjects, 103 primary hyperlipidaemia without history of such diseases and 106 angiographically documented CHD patients. RESULTS: The frequencies of PON1 192R allele and 192RR genotype were significantly higher in CHD patients than in normal control subjects (P = 0.009 and 0.037, respectively). The significantly higher frequencies of 55M allele and 55LM genotype were also observed in CHD patients (P = 0.037 and P = 0.034, respectively). The frequencies of both PON1 polymorphisms were not different in primary hyperlipidaemia as compared to the normal control subjects. The odds ratio (OR) of 192RR genotype and 192R allele for CHD were 2.84 (1.17-6.99, P = 0.011) and 1.70 (1.11-2.61, P = 0.009), respectively. The age-adjusted OR for CHD was 2.72 (1.25-5.94, P = 0.012). These frequencies of both PON1 alleles were similar to those seen in other Asian populations. CONCLUSIONS: The association between PON1 polymorphisms and CHD risk was demonstrated in aThai population. These new data underscore the essence of ethnic variations in the interpretation of CHD associated with PON1 polymorphism.

Lipid peroxidation and antioxidant enzyme activities in erythrocytes of type 2 diabetic patients.

BACKGROUND AND OBJECTIVE: Although diabetes mellitus (DM) patients are claimed to be under oxidative stress because of prolonged exposure to hyperglycemia, the influence of glycemic control and cardiovascular complication in diabetes on oxidative stress parameters has not been fully studied. The present study aimed to investigate lipid peroxidation end product (malondialdehyde, MDA) and antioxidant enzymes in fairly controlled type 2 DM (fasting plasma glucose [FPG] < or = 180 mg/dl) or type 2 DM complicated with coronary heart disease (CHD) and poorly controlled type 2 DM (FPG > 180 mg/dl) in comparison to a normal healthy group (FPG < 110 mg/dl). MATERIAL AND METHOD: MDA and antioxidant enzymes such as superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase (CAT) were determined in the red cell of 19 subjects with poorly controlled type 2 DM, 26 subjects with fairly controlled type 2 DM and 20 subjects with type 2 DM complicated with CHD who were matched for age and gender. Twenty healthy subjects with normal plasma glucose level and matched for age and gender were served as a control group. In all groups of DM these oxidative stress parameters were compared to a control group by one-way ANOVA test. Pearson rank correlation coefficient was used to compare the relationship between FPG and oxidative stress status in type 2 DM and normal controls. RESULTS: The red cell MDA levels were significantly higher in all types of diabetes compared to age-matched normal controls. The mean of red cell MDA level was highest in type 2 DM complicated with CHD. Red cell antioxidant enzyme activities were also significantly increased except for SOD and GPx activities in fairly controlled type 2 DM. The significant positive correlation between oxidative stress status (as MDA and CAT) and FPG was found in poorly controlled type 2 DM and type 2 DM complicated with CHD whereas in fairly controlled type 2 DM the significant positive correlation between CAT and FPG was only observed. CONCLUSION: These findings strongly confirmed the evidence that diabetic patients were susceptible to oxidative stress and higher blood glucose level had an association with free radical-mediated lipid peroxidation. The highest level of MDA in type 2 DM complicated with CHD suggested that oxidative stress played an important role in the pathogenesis of cardiovascular complication. The results also showed the increase in antioxidant enzymes. These could probably be due to adaptive response to pro-oxidant in diabetic state. Hence, there seems to be imbalance between oxidant and antioxidant systems in type 2 diabetic patients.

A prospective randomized study to assess the efficacy of rate and site of atrial pacing on long-term development of atrial fibrillation.

The Septal Pacing for Atrial Fibrillation Suppression Evaluation (SAFE) study is a single-blinded, parallel randomized designed multicenter study in pacemaker indicated patients with paroxysmal atrial fibrillation (AF). The objective is to evaluate whether the site of atrial pacing--conventional right atrial appendage versus low atrial septal--with or without atrial overdrive pacing will influence the development of persistent AF. The study will provide a definitive answer to whether a different atrial pacing site or the use of AF suppression pacing or both can give incremental antiarrhythmic benefit when one is implanting a device for a patient with a history of paroxysmal AF.

One-year outcome of cardioversion of atrial fibrillation in patients with mitral stenosis after percutaneous balloon mitral valvuloplasty.

Our objectives were to study the success rate of electrical cardioversion after percutaneous balloon mitral valvuloplasty (PBMV) in patients with symptomatic moderate-to-severe mitral stenosis and atrial fibrillation (AF) and the maintenance rate of sinus rhythm for < or =1 year. We studied patients with mitral stenosis and AF who were scheduled for PBMV. Electrical cardioversion was performed 1 month after PBMV. Amiodarone 200 mg/day was started the day after PBMV. The primary outcomes studied were the rate of successful cardioversion and the maintenance rate of sinus rhythm at 12 months. Of 272 patients scheduled for PBMV, 70 were enrolled. The average age was 45 +/- 10 years. The average mitral valve area was 0.82 +/- 0.22 cm(2). Cardioversion was successful in 50 patients (71%). Logistic regression analysis revealed that left atrial size and associated aortic valvular disease were predictors of successful cardioversion. Of the 50 patients with successful cardioversion, AF recurred in 24 (48%). An increased left atrial diameter was the only factor associated with AF recurrence at 12 months. In conclusion, good candidates for cardioversion after PBMV were those with a left atrial diameter of <60 mm and no associated aortic valvular disease -- approximately 43% of patients with AF scheduled for PBMV. In this group, about 2/3 were in sinus rhythm at 12 months after cardioversion.

Plasma lipid peroxidation and antioxidiant nutrients in type 2 diabetic patients.

BACKGROUND AND OBJECTIVE: Observation shows diabetic patients to be more prone to oxidative stress because of hyperglycemia. The elevation of free radical production by this hyperglycemic production may exacerbate cardiovascular complication in diabetes. This study aims to investigate the oxidative stress related parameters in type 2 DM. Since the effects of glycemic control and cardiovascular complications in DM on these parameters has been not fully determined, the comparison between plasma MDA (malondialdehyde) and antioxidant nutrients with their age-matched normal healthy group may be used to determine the susceptibility of oxidative stress in this type of DM. MATERIAL AND METHOD: MDA and antioxidant nutrients (vitamin A, C, E and beta-carotene) were analyzed in plasma of 19 subjects with poorly controlled type 2 DM (fasting plasma glucose [FPG] > 180 mg/dl), 26 subjects with fairly controlled type 2 DM (FPG < or = 180 mg/dl), and 20 subjects with type 2 DM complicated coronary heart disease (CHD) who were matched for age and gender. Twenty healthy subjects with normal plasma glucose level (FPG < 110 mg/dl) and matched for age and gender served as a control group. In all groups of DM these oxidative stress parameters were compared to a normal group. RESULTS: The plasma MDA levels were significantly higher in all types of DM compared to age-matched normal control. Plasma antioxidant vitamin C and E significantly lower only in poorly controlled and CHD complicated type 2 DM, respectively. The mean of plasma vitamin E level was lowest in type 2 DM complicated with CHD. No significant differences in both plasma vitamin A and beta-carotene were noted between any types of DM and age-matched normal healthy group. The positive correlation between MDA and FPG was demonstrated in most group of patients with their normal subjects except in fairly controlled type 2 DM and negative correlation between vitamin E and FPG was also demonstrated in type 2 DM with CHD. CONCLUSION: These findings suggested that diabetic patients were susceptible to oxidative stress and higher plasma glucose level had an association with free radical-mediated lipid peroxidation. The lowest level of vitamin E in type 2 DM complicated with CHD indicated that oxidative stress played an important role in cardiovascular complication and vitamin E supplementation may be necessary for treatment and prevention in this group of diabetics.

An International Observational Prospective Survey Assessing the Control of Atrial Fibrillation in Asia-Pacific: Results of the Record-AFAP Registry.

A prospective 1-year observational survey was designed to assess the management and control of atrial fibrillation (AF) in eight countries within the Asia-Pacific region. Patients (N = 2,604) with recently diagnosed AF or a history of AF ≤1 year were included. Clinicians chose the treatment strategy (rhythm or rate control) according to their standard practice and medical discretion. The primary endpoint was therapeutic success. At baseline, rhythm- and rate-control strategies were applied to 35.7% and 64.3% of patients, respectively. At 12 months, therapeutic success was 43.2% overall. Being assigned to rhythm-control strategy at baseline was associated with a higher therapeutic success (46.5% vs 41.4%; P = 0.0214) and a lower incidence of clinical outcomes (10.4% vs 17.1% P < 0.0001). Patients assigned to rate-control strategies at baseline had higher cardiovascular morbidities (history of heart failure or valvular heart disease). Cardiovascular outcomes may be less dependent on the choice of treatment strategy than cardiovascular comorbidities.

One-year outcome after radiofrequency catheter ablation of symptomatic ventricular arrhythmia from right ventricular outflow tract.

Although ventricular premature complexes (VPCs) in patients without structural heart disease are benign, many patients experience disabling symptoms. Many patients need long-term medication, which is often ineffective and may have adverse effects. Radiofrequency catheter ablation (RFCA) may be an alternative treatment. RFCA was performed in 33 patients with severely symptomatic VPCs that were refractory to medication. Mean VPCs were 23,987 +/- 2,077 beats/24 hours. Twenty-four-hour ambulatory electrocardiographic monitoring, quality of life, and symptoms were assessed at a screening visit and 1 and 12 months after RFCA. RFCA was successfully performed in 32 patients (97%). This resulted in a significant improvement in symptoms, severity of ventricular arrhythmia, and quality of life at 1 and 12 months after the procedure. There were no major complications related to the procedure. Eight patients (24%) had residual arrhythmia. Five of them underwent repeated ablation with successful results. Thus, catheter ablation is a safe and effective treatment for symptomatic ventricular arrhythmia from the right ventricular outflow tract. It also improves the quality of life. Catheter ablation is a viable alternative to drugs in the presence of disabling symptoms.

Radiofrequency ablation for atrial fibrillation.

There have been a lot of progression in the treatment of atrial fibrillation during the last 10 years. Atrial fibrillation treatment is not only focus on prevention of thromboembolic comlications of this tachyarrhythmia but also on heart rate control which can be obtained in many ways. Recently, more information of atrial fibrillation mechanism led to new treatment modalities including surgery and the use of radiofrequency ablation. However, most of these new treatment forms are still investigational, evolving and reserved to atrial fibrillation patients who are refractory to standard treatment.

Radiofrequency catheter ablation for various tachyarrhythmias: experience in the Bangkok Heart Institute.

UNLABELLED: Radiofrequency catheter ablation (RFCA) is the first-line therapy for various tachyarrhythmias. The authors reports experience of RFCA for various types of tachyarrhythmia in 80 consecutive patients, 85 tracts of ablation, from May 2001 to October 2002. The mean age was 40 years, range 6-81 years. Seventy four and 13 tracts of ablation were supraventricular and ventricular arrhythmia, respectively. The results are shown below. [table: see text] CONCLUSION: RFCA is an effective method to cure various types tachyarrhythmia. Long-term follow-up should be evaluated in patients with paroxysmal atrial fibrillation.

Successful implantation of transveneous biventricular permanent pacemaker for refractory congestive heart failure: the first case-report in Thailand.

Biventricular pacemaker is a pacemaker that can pace both the right and left ventricle at the same time. There have been progression in the development of biventricular pacemaker from thoracotomy system to fully transveneous system. The benefit in improving quality of life in selected medical refractory congestive heart failure patients of this device had been shown in randomized controlled trials. The authors reported successful implantation fully transveneous biventricular pacemaker in Thailand.

Radiofrequency catheter ablation of ventricular tachycardia from right ventricular outflow tract.

From January 1996 to May 2002, 61 patients with ventricular tachycardia from right ventricular outflow tract were referred to Siriraj hospital. All patients underwent clinical examination, Doppler echocardiography and electrophysiologic study. Mapping of ventricular tachycardia was performed by activation mapping and pacemapping. There were 44 females and 17 males with an average age of 41.7 +/- 9.9 years. Presenting symptoms were palpitation (95.1%), presyncope (39.3%), and syncope (26.2%). Six patients were found to have underlying cardiac disease. Radiofrequency catheter ablation was successful in 56 patients (91.8%). There were no major complications. Seven patients (12.5%) had recurrent ventricular tachycardia. Five of them were successfully reablated. The authors concluded that radiofrequency ablation is an effective treatment in patients with ventricular tachycardia from right ventricular outflow tract.